Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsors and Collaborators: |
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) University of Pittsburgh |
---|---|
Information provided by: | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) |
ClinicalTrials.gov Identifier: | NCT00022854 |
Anterior cruciate ligament (ACL) reconstruction is surgery that is done to repair a damaged ligament in the knee. In this study we will look at whether the femoral nerve block, a commonly used method for pain relief after ACL reconstruction, affects the way patients feel after surgery. We will study recovery during the first week after surgery and also 3-12 weeks after surgery. We will give all patients spinal anesthesia. Some patients will also receive a continuous femoral nerve block for 2 days, or by a single injection. We predict that patients who received the nerve block will have significantly improved pain results, compared to patients who did not receive the nerve block.
Condition | Intervention | Phase |
---|---|---|
Anterior Cruciate Ligament Rupture |
Procedure: Single-injection femoral nerve block Procedure: Femoral nerve block 60-hour continuous injection Procedure: Saline (control) injection into femoral nerve envelope |
Phase IV |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Parallel Assignment, Efficacy Study |
Official Title: | Outcomes After ACL Reconstruction: The Effect of Femoral Nerve Block Analgesia |
Enrollment: | 270 |
Study Start Date: | May 2001 |
Study Completion Date: | January 2005 |
Arms | Assigned Interventions |
---|---|
1: Placebo Comparator |
Procedure: Saline (control) injection into femoral nerve envelope
Nerve block bolus with 30 mL saline, followed by continuous saline infusion
|
2: Experimental
Nerve block bolus with 30 mL levobupivacaine 0.25%, followed by continuous saline infusion
|
Procedure: Single-injection femoral nerve block
Nerve block bolus with 30 mL levobupivacaine 0.25%, followed by continuous saline infusion
|
3: Experimental
Nerve block bolus with 30 mL levobupivacaine 0.25%, followed by continuous levobupivacaine infusion of 5 mL/hr for 50 hr
|
Procedure: Femoral nerve block 60-hour continuous injection
Nerve block bolus with 30 mL levobupivacaine 0.25%, followed by continuous infusion (5 mL/hr for 50 hours) of 0.25% levobupivacaine
|
In this project, we will measure outcomes of anesthesia and pain management for common orthopedic procedures. The influence of nerve block pain management on outcomes after outpatient anterior cruciate ligament (ACL) reconstruction has not been studied, especially the patient's potential to return to societal productivity during the first week after surgery. Therefore, we have designed a randomized clinical trial to study the role of nerve block pain management techniques on patient outcomes during the first week after surgery and on recovery 3-12 weeks after surgery. Our hypothesis is that patients undergoing nerve block analgesia will manifest better self-reported recovery outcomes, physical function outcomes, and objective measures of neuromuscular function.
We will give consenting patients (n=270) undergoing ACL reconstruction conventional spinal anesthesia and will randomize them to receive femoral nerve block analgesia with either a single injection, a continuous infusion for 2 days, or saline placebo. We will use goniometry to test postoperative range of motion in extension to determine whether the quadriceps femoris torque output is impaired. We will compare patient-reported recovery outcomes across treatment groups using three validated health status measures suitable for daily assessment (Verbal Pain Score, SF-8, and the Quality of Recovery [from anesthesia, QoR-40] Score).
We aim to determine the quality of immediate recovery from anesthesia and the extent of reported pain. We will compare the effects of single injection and continuous infusion on femoral nerve analgesia to determine the better dosing strategy for these patients.
Ages Eligible for Study: | 14 Years to 65 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
United States, Pennsylvania | |
University of Pittsburgh Medical Center, Center for Sports Medicine | |
Pittsburgh, Pennsylvania, United States, 15203 |
Principal Investigator: | Brian A. Williams, MD, MBA | University of Pittsburgh |
Responsible Party: | University of PIttsburgh ( Allen DiPalma, Director - Office of Research ) |
Study ID Numbers: | K23 AR47631, NIAMS-066 |
Study First Received: | August 14, 2001 |
Last Updated: | December 14, 2007 |
ClinicalTrials.gov Identifier: | NCT00022854 History of Changes |
Health Authority: | United States: Federal Government |
ACL Nerve block Knee Outcome survey |
Anesthesia Analgesia Pain |
Levobupivacaine Anesthetics Rupture Pain |